Interestingly, DYRK2 upregulation in purified CML LSCs was associated with depletion of c-MYC protein and elevated levels of p53 phosphorylated at Ser 46, and inhibition of the proteasome allowed accumulation of c-MYC protein phosphorylated at Ser 62 (the DYRK2 site) and Thr 58 (the GSK3 site). This evidence concerns the gene DYRK2 and chronic myelogenous leukemia, BCR-ABL1 positive.